Bausch + Lomb Ultra (samfilcon A) Contact Lenses
Bausch and Lomb, Inc., · Decision date Apr 30, 2018
What did the FDA approve?
The FDA approved Bausch + Lomb Ultra (samfilcon A) contact lenses on April 30, 2018. The approval covers three lens configurations: single vision spherical, presbyopia, and astigmatism. Each is indicated for extended wear up to 7 days between removals for cleaning, disinfection, or disposal, as recommended by the eye care practitioner.
The single vision spherical lens corrects myopia and hyperopia in aphakic or non-aphakic persons with non-diseased eyes and astigmatism of 2.00 diopters or less. The presbyopia lens adds correction for presbyopia with add powers from +0.75D to +5.00D. The astigmatism lens corrects astigmatism up to 5.00 diopters. The statement reports intended use, not independent proof of safety or effectiveness.
FDA approval order statement
Approval for the Bausch + Lomb Ultra (samfilcon A) Contact Lenses. These devices are indicated for:Single Vision Spherical (SVS) Vision CorrectionThe BAUSCH + LOMB ULTRA (samfilcon A) Contact Lens is indicated for extended wear for up to 7 days between removals for cleaning and disinfection or disposal of the lens, as recommended by the eye care practitioner. The lens is indicated for the correction of refractive ametropia (myopia and hyperopia) in aphakic and/or not-aphakic persons with non-diseased eyes, exhibiting astigmatism of 2.00 diopters or less, that does not interfere with visual acuity.Presbyopia Vision CorrectionThe BAUSCH + LOMB ULTRA (samfilcon A) Contact Lens for Presbyopia is indicated for extended wear for up to 7 days between removals for cleaning and disinfection or disposal of the lens, as recommended by the eye care practitioner. The lens is indicated for the correction of refractive ametropia (myopia, hyperopia and astigmatism) and presbyopia in aphakic and/or not-aphakic persons with non-diseased eyes, exhibiting astigmatism of 2.00 diopters or less, that does not interfere with visual acuity. The lens may be prescribed for add powers ranging from +0.75D to +5.00D. Astigmatism Vision CorrectionThe BAUSCH + LOMB ULTRA (samfilcon A) Contact Lens for Astigmatism is indicated for extended wear for up to 7 days between removals for cleaning and disinfection or disposal of the lens, as recommended by the eye care practitioner. The lens is indicated for the correction of refractive ametropia (myopia, hyperopia and astigmatism) in aphakic and/or not-aphakic persons with non-diseased eyes, exhibiting astigmatism up to 5.00 diopters.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Ophthalmic
- Decision date
- Apr 30, 2018
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P170035
- Regulatory pathway
- Premarket approval application
- Applicant
- Bausch and Lomb, Inc.,
- Product code
- LPM
- Decision code
- APPR
- Decision date
- Apr 30, 2018
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lenses, soft contact, extended wear.
- Applicant
- Bausch and Lomb, Inc.,
- Product code
- LPM
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P170035 received
Application receipt date recorded by FDA.
P170035 · FDA decision
APPR
P170035/S021 · Related supplement
Bausch + Lomb Ultra (samfilcon A) Contact Lenses
Timeline entries are records held by MedtechLedger for P170035. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170035
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Bausch + Lomb Ultra (samfilcon A) Contact LensesP170035/S021 | Bausch and Lomb, Inc., | PMA supplement | Sep 14, 2026 | FDA |
Explore the linked device profile
Other records with product code LPM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VISTAKON (senofilcon A) Brand Contact LensesP040045/S147 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 16, 2026 | FDA |
VISTAKON (SENOFILCON A) Brand Contact LensesP040045/S146 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 8, 2026 | FDA |
| Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Sep 2, 2026 | FDA | |
BIOFINITY (COMFILCON A)P080011/S204 | CooperVision, Inc. | PMA supplement | Sep 2, 2026 | FDA |
BIOFINITY (COMFILCON A)P080011 | CooperVision, Inc. | PMA approval | Nov 19, 2008 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bausch and Lomb, Inc.,
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1400 N. Goodman St., Rochester, NY, 14609
Sources and methodology
- Original FDA record: P170035
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


